Literature DB >> 19805477

Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.

David Vaudry1, Anthony Falluel-Morel, Steve Bourgault, Magali Basille, Delphine Burel, Olivier Wurtz, Alain Fournier, Billy K C Chow, Hitoshi Hashimoto, Ludovic Galas, Hubert Vaudry.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino acid C-terminally alpha-amidated peptide that was first isolated 20 years ago from an ovine hypothalamic extract on the basis of its ability to stimulate cAMP formation in anterior pituitary cells (Miyata et al., 1989. PACAP belongs to the vasoactive intestinal polypeptide (VIP)-secretin-growth hormone-releasing hormone-glucagon superfamily. The sequence of PACAP has been remarkably well conserved during evolution from protochordates to mammals, suggesting that PACAP is involved in the regulation of important biological functions. PACAP is widely distributed in the brain and peripheral organs, notably in the endocrine pancreas, gonads, respiratory and urogenital tracts. Characterization of the PACAP precursor has revealed the existence of a PACAP-related peptide, the activity of which remains unknown. Two types of PACAP binding sites have been characterized: type I binding sites exhibit a high affinity for PACAP and a much lower affinity for VIP, whereas type II binding sites have similar affinity for PACAP and VIP. Molecular cloning of PACAP receptors has shown the existence of three distinct receptor subtypes: the PACAP-specific PAC1-R, which is coupled to several transduction systems, and the PACAP/VIP-indifferent VPAC1-R and VPAC2-R, which are primarily coupled to adenylyl cyclase. PAC1-Rs are particularly abundant in the brain, the pituitary and the adrenal gland, whereas VPAC receptors are expressed mainly in lung, liver, and testis. The development of transgenic animal models and specific PACAP receptor ligands has strongly contributed to deciphering the various actions of PACAP. Consistent with the wide distribution of PACAP and its receptors, the peptide has now been shown to exert a large array of pharmacological effects and biological functions. The present report reviews the current knowledge concerning the pleiotropic actions of PACAP and discusses its possible use for future therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805477     DOI: 10.1124/pr.109.001370

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  406 in total

1.  IL-6 and PACAP receptor expression and localization after global brain ischemia in mice.

Authors:  Tomoya Nakamachi; Masashi Tsuchida; Nobuyuki Kagami; Sachiko Yofu; Yoshihiro Wada; Motohide Hori; Daisuke Tsuchikawa; Akira Yoshikawa; Nori Imai; Keisuke Nakamura; Satoru Arata; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2012-06-06       Impact factor: 3.444

Review 2.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

Review 3.  Ion channels and signaling in the pituitary gland.

Authors:  Stanko S Stojilkovic; Joël Tabak; Richard Bertram
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

4.  Stimulation of the hypothalamic ventromedial nuclei by pituitary adenylate cyclase-activating polypeptide induces hypophagia and thermogenesis.

Authors:  Jon M Resch; Joanne P Boisvert; Allison E Hourigan; Christopher R Mueller; Sun Shin Yi; Sujean Choi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-28       Impact factor: 3.619

5.  Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.

Authors:  Venkat Subramaniam; Gin Chuang; Huijing Xia; Brendan Burn; Jessica Bradley; Jerome L Maderdrut; David H Coy; Kurt J Varner
Journal:  Peptides       Date:  2017-07-15       Impact factor: 3.750

6.  Influence of terminal differentiation and PACAP on the cytokine, chemokine, and growth factor secretion of mammary epithelial cells.

Authors:  Katalin Csanaky; Wolfgang Doppler; Andrea Tamas; Krisztina Kovacs; Gabor Toth; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2013-12-10       Impact factor: 3.444

Review 7.  Targeting BKCa Channels in Migraine: Rationale and Perspectives.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Christian Gram; Cherie Amalie Waldorff Nielsen; Messoud Ashina
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

Review 8.  Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Signaling and the Dark Side of Addiction.

Authors:  Olivia W Miles; Victor May; Sayamwong E Hammack
Journal:  J Mol Neurosci       Date:  2018-08-03       Impact factor: 3.444

9.  PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.

Authors:  Terry W Moody; Lingaku Lee; Tatiana Iordanskaia; Irene Ramos-Alvarez; Paola Moreno; Howard E Boudreau; Thomas L Leto; Robert T Jensen
Journal:  Peptides       Date:  2018-09-28       Impact factor: 3.750

10.  Pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1) gene is suppressed by transglutaminase 2 activation.

Authors:  Ayako Miura; Yuki Kambe; Kazuhiko Inoue; Hideki Tatsukawa; Takashi Kurihara; Martin Griffin; Soichi Kojima; Atsuro Miyata
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.